{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T23:12:13.806129+00:00","company":{"ticker":"LTRN","cik":1763950,"company_name":"Lantern Pharma Inc."},"pagination":{"limit":100,"returned":4,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"e75388d884ed386c293b981b102d15667e929aa3","cik":1763950,"ticker":"LTRN","company_name":"Lantern Pharma Inc.","filed_at":"2026-03-30T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fiscal year and fourth quarter ended December 31, 2025","report_date":"2026-03-30","result_type":"reported_results","revenue_text":null},"claim":"Lantern Pharma Inc. reported financial results for the fiscal year and fourth quarter ended December 31, 2025.","evidence_excerpt":"On March 30, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the fiscal year and fourth quarter ended December 31, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-013608","anchor_url":"https://secwatch.observer/filing/0001493152-26-013608#claim-e75388d884ed386c293b981b102d15667e929aa3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226013608/0001493152-26-013608-index.htm"},{"fact_type":"governance_change","fact_key":"a84de241aa1d3de0f55714807fc1219fe66ea241","cik":1763950,"ticker":"LTRN","company_name":"Lantern Pharma Inc.","filed_at":"2025-07-29T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2025-07-24","item_codes_triggered":["5.03"],"summary_text":"Reduced quorum requirement for stockholder meetings from a majority to one-third (33.33%) of shares entitled to vote"},"claim":"Lantern Pharma Inc.: Reduced quorum requirement for stockholder meetings from a majority to one-third (33.33%) of shares entitled to vote (effective 2025-07-24).","evidence_excerpt":"On July 24, 2025, the Board approved an amendment to the Company’s By-laws (the “By-laws”), effective immediately. The amendment modified the provisions for determining a quorum for a meeting of stockholders of the Company and effectively reduced the quorum requirement from a majority of the shares entitled to vote at the meeting to one-third (33.33%) of the shares entitled to vote at the meeting.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-021407","anchor_url":"https://secwatch.observer/filing/0001641172-25-021407#claim-a84de241aa1d3de0f55714807fc1219fe66ea241","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1763950/000164117225021407/0001641172-25-021407-index.htm"},{"fact_type":"earnings_release","fact_key":"38d97d338a28e35a54984ef8c371b58d0547c2ec","cik":1763950,"ticker":"LTRN","company_name":"Lantern Pharma Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":null},"claim":"Lantern Pharma Inc. reported financial results for the first quarter 2024.","evidence_excerpt":"On May 9, 2024, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the first quarter ended March 31, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-018426","anchor_url":"https://secwatch.observer/filing/0001493152-24-018426#claim-38d97d338a28e35a54984ef8c371b58d0547c2ec","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315224018426/0001493152-24-018426-index.htm"},{"fact_type":"earnings_release","fact_key":"61cf6ca63ebb97b4e4115b92e138e3db1295fad8","cik":1763950,"ticker":"LTRN","company_name":"Lantern Pharma Inc.","filed_at":"2024-03-18T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and fiscal year ended December 31, 2023","report_date":"2024-03-18","result_type":"reported_results","revenue_text":null},"claim":"Lantern Pharma Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_excerpt":"On March 18, 2024, Lantern Pharma Inc. (the \"Company\") will issue a press release announcing its financial results for the fiscal year and fourth quarter ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-010303","anchor_url":"https://secwatch.observer/filing/0001493152-24-010303#claim-61cf6ca63ebb97b4e4115b92e138e3db1295fad8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315224010303/0001493152-24-010303-index.htm"}]}